Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 106.16

+4.0%

3:48 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (769)	11/4/1998 1:21:00 PM
From: Rocketman	Read Replies (1) of 3202

1.2M ESTs is probably the biggest collection filed at the PTO. If you figure an EST of say 100-300 base pairs (big assumption), this represents maybe 3-10% of the 3 billion human base pairs. But, INCY focuses on the coding regions of the genome and not the "junk DNA", so it is probably a larger percentage of the coding genes. As far as the number of Protein Kinases in a patent, this seems like the PTO is letting them lock up certain categories at a time. If you are a company developing protein kinases, yeah 44 is a lot, especially if one of them covers the protein you are developing. Re: runners up, (but this is still good for them) - HGSI, who has become more of a pharma than a genomics. Hyseq - who is late in the game and just not very believable. Celera who is getting started half a decade and a genome too late. This is great for all the genomics companies, not just INCY as it sets the trend for the future. Who this really impacts is anyone developing products who actually wants to sell them and make money on them, and thus needs clear intellectual property rights. This act by the PTO has just made a huge validation of the genomics companies futures. Rman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next